This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Relationship Disclosure: Semaglutide Watchdog and its publisher, US Peptides Partners LLC, have no ownership, affiliate, referral, advertising, management, reviewer, or other material financial relationship with certain providers listed on this website. All providers are evaluated using the same documented evidence, pricing, and verification methodology, regardless of relationship status.
GLP-1 Membership Fees Explained (2026)
Many GLP-1 programs split cost into a membership fee plus medication. We explain how to find the true total.
Quick answer
Brand GLP-1 prices collapsed in late 2025 and most comparison pages have not caught up. As of July 12, 2026, brand Zepbound is $299–$449/month through LillyDirect, brand Wegovy is $349 through NovoCare (the oral Wegovy tablet is $149), and either drops to about $25 with commercial coverage that includes it. Retail list prices are $1,086 (Zepbound) and $1,349 (Wegovy). Compounded programs advertise $99–$299 — but they are not FDA-approved and their legal basis narrowed sharply in 2025. All brand figures here are verified against manufacturer sources.
Cost by pathway
Bars use the low end of each pathway's range. Compounded and all-inclusive cash options sit far below retail brand pricing — the tradeoff is FDA-approval status.
| Pathway | Typical cost | Notes | Status |
|---|---|---|---|
| Wegovy tablets (oral semaglutide, brand) | $149/month | NovoCare; 1.5mg & 4mg. 4mg at this price to Aug 31, 2026 | Verified |
| Zepbound 2.5 mg (brand, LillyDirect) | $299/month | Starting dose; no refill-window condition | Verified |
| Wegovy standard (brand, NovoCare) | $349/month | Cut from $499 in Nov 2025. $199 first 2 fills for new patients | Verified |
| Ozempic standard (brand, NovoCare) | $349/month | 0.25-1mg; 2mg is $499 | Verified |
| Zepbound 5 mg (brand, LillyDirect) | $399/month | No refill-window condition | Verified |
| Zepbound 7.5-15 mg (brand, LillyDirect) | $449/month | ONLY if refilled within 45 days of last delivery | Verified |
| Zepbound 10-15 mg — 45-day window missed | $699/month | The penalty rate. A $250/month mistake | Verified |
| Brand + commercial insurance + savings card | as low as $25/month | Zepbound or Wegovy, if your plan covers it | Verified |
| Medicare GLP-1 Bridge (Wegovy) | $50/month | Eligible Part D beneficiaries, Jul 1 2026 - Dec 31 2027 | Verified |
| Retail Zepbound pen (list price) | $1,086/month | What you pay with no program at all | Verified |
| Retail Wegovy (list price) | $1,349/month | What you pay with no program at all | Verified |
| Compounded GLP-1 (telehealth) | $110-$399/month | NOT FDA-approved. Legal basis narrowed sharply in 2025 | Verified |
Why we label prices instead of just listing themA caution about every compounded-price figure you will read anywhere, including on this page. Comparison sites in this category publish flatly contradictory numbers for the same providers — we have seen the same program listed at $179 on one site and $259 on another in the same month, and 'cheapest tirzepatide' claims ranging from $99 to $169 depending on who is writing. Advertised rates also frequently apply only to a first month, a starter dose, or a 12-month prepaid commitment.
We therefore label every provider price with its evidence status rather than presenting all figures as equally solid, and we treat any compounded price we have not captured ourselves as Reported, not Verified. Brand pricing on this page is verified directly against manufacturer sources, which is why we lead with it.
We therefore label every provider price with its evidence status rather than presenting all figures as equally solid, and we treat any compounded price we have not captured ourselves as Reported, not Verified. Brand pricing on this page is verified directly against manufacturer sources, which is why we lead with it.
Every fee that can be attached to a GLP-1 programme
| Line item | What to ask | How often it bites |
|---|---|---|
| Advertised starting price | Is this a first-month or introductory rate? | Very often — TrimRx, MEDVi, Noom, Eden all advertise intro rates |
| Ongoing price | What do I pay in month two? | This is the number that matters |
| Membership fee | Is it required, and is it billed separately? | Very often — Eden, Mochi, Hims, Hers, Ro, PlushCare |
| Consultation fee | Is the initial visit billed separately? | Sometimes — PlushCare charges $129 initially |
| Laboratory fee | Are baseline labs included or billed to me? | Varies; often unstated until intake |
| Shipping | Included? Expedited? Cold-chain? | Usually included; confirm it |
| Supplies | Are syringes, needles and sharps disposal included? | Usually included on all-inclusive plans |
| Dose-based increase | What do I pay at the highest dose you cover? | Material — MEDVi goes $399 to $499; Shed and Oak escalate |
| Dose ceiling / cap | Is there a maximum dose on this plan? | Material — Noom's $199 plan caps at 0.6mg |
| Upfront payment | How much do I pay today to get the advertised rate? | Found's $169 requires roughly $2,028 up front |
| Renewal price | Does the price change when the plan renews? | Frequently unstated — get it in writing |
| Cancellation terms | If I stop in month three of twelve, what happens to my money? | The most-forgotten question in the category |
A worked example
| Programme A (advertised $179) | Programme B (advertised $186) | |
|---|---|---|
| Month 1 | $179 (intro rate) | $186 |
| Months 2-12 (ongoing rate) | $299 × 11 = $3,289 | $186 × 11 = $2,046 |
| Membership (if any) | $0 | $0 |
| Dose-based increase | None stated | None — flat at every dose |
| Twelve-month total | $3,468 | $2,232 |
| Effective monthly | $289 | $186 |
Why the ranking rule matters more than the rankingThis is the entire reason we sort every table on this site by ongoing total cost rather than by advertised price. It is not a clever methodology. It is just the one that does not produce a false ranking.
Brand pricing, verified against the manufacturers
| Dose | Self-pay price | Condition |
|---|---|---|
| 2.5 mg (starting dose) | $299/mo | No refill-window condition |
| 5 mg | $399/mo | No refill-window condition |
| 7.5 mg | $449/mo | Only if refilled within 45 days — otherwise $499 |
| 10 mg | $449/mo | Only if refilled within 45 days — otherwise $699 |
| 12.5 mg | $449/mo | Only if refilled within 45 days — otherwise $699 |
| 15 mg (maintenance) | $449/mo | Only if refilled within 45 days — otherwise $699 |
The 45-day trapThe 45-day clock runs from the delivery date of your previous shipment, not the order date. Miss it at 10 mg or above and the price jumps from $449 to $699 — a $250 penalty for being a week late. This is the single most expensive piece of fine print in the category.
| Dose | Price inside window | Price outside window | Penalty |
|---|---|---|---|
| 7.5 mg | $449 | $499 | +$50 |
| 10 mg | $449 | $699 | +$250 |
| 12.5 mg | $449 | $699 | +$250 |
| 15 mg | $449 | $699 | +$250 |
Prices at 7.5 mg and above hold only if you refill within 45 days of the previous delivery. Outside that window the same doses cost $499-$699.
| Product / dose | Self-pay price | Notes |
|---|---|---|
| 0.25 mg / 0.5 mg (first 2 fills, new patients) | $199/mo | Introductory offer through Dec 31, 2026 |
| 0.25–2.4 mg (standard, after intro) | $349/mo | Cut from $499 in November 2025 |
| Wegovy HD 7.2 mg | $399/mo | |
| Wegovy tablets 1.5 mg / 4 mg (oral) | $149/mo | 4 mg at this price through Aug 31, 2026, then $199 |
The finding that changes the decision
The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of July 12, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.
For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.
For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.
Brand figures are verified against manufacturer pricing pages. The compounded figure is the lowest advertised rate we have seen and is unverified. Note where the brand oral tablet sits.
Pricing is time-sensitiveThese figures change frequently. The date above is the last verification; treat any pricing older than a month as provisional.
How we normalize total cost
Compounding statusCompounded drugs are <b>not FDA-approved</b>: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are <b>essentially a copy</b> of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not.
Limitations of this analysis
Frequently asked questions
Why is compounded tirzepatide so much cheaper than Zepbound?
Can I get GLP-1 medication without insurance?
What is the cheapest legitimate option?
Sources
- Eli Lilly — LillyDirect Zepbound pricing page and Zepbound Self Pay Journey Program terms (CMAT-05333, 05/2026), captured July 12, 2026.
- Eli Lilly — press release, "Lilly lowers the price of Zepbound single-dose vials," December 1, 2025.
- Novo Nordisk — NovoCare Pharmacy pricing pages and Wegovy Price Guide, captured July 12, 2026.
- Novo Nordisk — press release, introductory self-pay offer for Wegovy and Ozempic, November 17, 2025.
- U.S. Food and Drug Administration — compounding status and enforcement history.
- Our normalization methodology.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
The caveats that belong with the numbersThree things must travel with every one of those numbers.
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
What the trials do and do not coverThe boundary of the evidence, for this treatment. Every efficacy figure on this page comes from a trial of an FDA-approved subcutaneous injection. None of it was collected on a compounded preparation, a microdose regimen, or an orally disintegrating tablet.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
Why titration decides your real priceTitration is where cost is actually decided, and almost no pricing page says so.
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded Semaglutide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
What the trials do and do not coverThe boundary of the evidence, for this treatment. Every efficacy figure on this page comes from a trial of an FDA-approved subcutaneous injection. None of it was collected on a compounded preparation, a microdose regimen, or an orally disintegrating tablet.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.